
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsHenlius Reports Longer Overall Survival With Serplulimab in ES-SCLCHenlius reported numerical overall survival differences favoring serplulimab over atezolizumab in the US ASTRIDE study in extensive-stage small cell lung cancer.Fact-Checked
Clinical TrialsMerck KGaA Reports Durable Tumor Control With Pimicotinib at Two YearsMerck KGaA reported two-year results from the Phase 3 MANEUVER study of pimicotinib in tenosynovial giant cell tumor (TGCT), showing a 76.2% RECIST response rate alongside sustained improvements…Fact-Checked
New Drug ApprovalAstraZeneca’s Enhertu Wins EU Approval in Early Breast CancerThe European Commission has approved AstraZeneca and Daiichi Sankyo’s Enhertu for adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.Fact-Checked
Clinical TrialsIambic’s IAM1363 Shows Early Activity Against Brain MetastasesIambic Therapeutics presented updated Phase 1/1b data for investigational HER2 inhibitor IAM1363 at ESMO 2026, reporting systemic and intracranial responses in heavily pretreated patients.Fact-Checked
New Drug ApprovalFDA Approves Pfizer’s TALZENNA Plus XTANDI for HRR-Mutated mHSPCPfizer’s TALZENNA plus XTANDI has received FDA approval for HRR-mutated metastatic hormone-sensitive prostate cancer.Fact-Checked
Clinical TrialsIncyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 TherapiesIncyte reported preliminary Phase 1 clinical activity for INCB161734 in KRAS G12D-mutated pancreatic and colorectal cancers and INCA33890 in advanced colorectal cancer.Fact-Checked
Clinical TrialsMirum Reports Positive Zilurgisertib Results in Children With FOPMirum Pharmaceuticals reported Phase 2 PROGRESS Cohort 2 results showing reduced heterotopic ossification lesion volume and improved joint mobility with zilurgisertib in children aged 6 to under 12…Fact-Checked
Clinical TrialsCorcept Reports Positive BELLA Results for Lifyorli TripletCorcept reports a 59% response rate and 7.2-month median PFS with Lifyorli, nab-paclitaxel and bevacizumab in Phase 2 BELLA.Fact-Checked
Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADTJohnson & Johnson reports that perioperative ERLEADA (apalutamide) plus androgen deprivation therapy reduced the hazard of event-free survival events by 62% versus surgery alone in high-risk localized or…Fact-Checked
Clinical TrialsAgenus Reports 72% Complete Response with BOT+BAL in dMMR Colon CancerAgenus reported a 72% pathologic complete response rate and an 83% major pathologic response rate after six weeks of neoadjuvant botensilimab plus balstilimab in 18 patients with locally…Fact-Checked
Clinical TrialsAstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS EndpointAstraZeneca’s Phase III CLARITY-Gastric01 trial found a significant overall-survival benefit with investigational sonesitatug vedotin in previously treated advanced CLDN18.2-positive gastric, gastroesophageal junction and oesophageal adenocarcinoma.Fact-Checked
Clinical TrialsJ&J Reports Strong Tumour Responses With RYBREVANT FASPROJohnson & Johnson reported a confirmed 77% overall response rate with subcutaneous RYBREVANT FASPRO, pembrolizumab and carboplatin in a subgroup of previously untreated patients with recurrent or metastatic…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.